|Name||Number of shares||% of issued share capital|
|Funds managed by Athyrium
Capital Management, LP
|Funds managed by Highbridge Capital Management LLC||15,732,313||8.8%|
|Novelion Therapeutics Inc||12,490,250||7.0%|
|Edgepoint Investment Group Inc.||12,126,650||6.8%|
|Stonepine Capital Management, LLC||11,082,415||6.2%|
|Funds managed by UBS O’Connor LLC||9,950,000||5.6%|
|AXA Investment Management||6,494,164||3.6%|
On August 31 2021 the issued share capital comprised 316,496,087 ordinary shares of 6 pence each (“Ordinary Shares”). The Company does not hold any Ordinary Shares in treasury. Therefore, the total number of voting rights in the Company at August 31, 2021 was 316,496,087.
This figure of 316,496,087 may be used by shareholders as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA’s Disclosure Guidance and Transparency Rules.
Pursuant to the AIM rules, and insofar as the Company is aware, as at 30 June 2021, 28.39% of the Company’s issued share capital is not in public hands.
Restrictions: there are no restrictions on the transfer of Ordinary Shares.
Takeover Code: the Company is subject to the City Code on Takeovers and Mergers.